Hepatotoxicity induced by tolvaptan: A case report Maria del Carmen Merino Bueno, Cristina Sango Merino, Anna Gallardo Pérez, Susana Rojo Alba, Carlos Ruiz Zorrilla, Miguel Angel de la Torre Fernández, Ana Maria Suárez Laures, Emilio Sánchez Álvarez

Clinical experience with different initial doses of tolvaptan in SIADH David E. Barajas-Galindo, Alfonso Vidal-Casariego, Emilia Gómez-Hoyos, Paula Fernández-Martínez, María Guerra González, Ana Hernández-Moreno, Miran Alejo-Ramos, Rocío Villar-Taibo, Isidoro Cano-Rodríguez, María D. Ballesteros-Pomar

Is tolvaptan (a vasopressin V2 receptor antagonist) effective in the management of isovolumic and hypervolaemic hypernatremia? F. Ortiz